Multisystem Inflammatory Syndrome in Children Admitted to a Tertiary Pediatric Intensive Care Unit
Authors:
- Emrah GünEGEmrah Gün
- Tanıl KendirliTKTanıl Kendirli
- Edin BotanEBEdin Botan
- Nazmiye TürkerNTNazmiye Türker
- Anar GurbanovAGAnar Gurbanov
- Burak BalabanBBBurak Balaban
- Ali Genco GencayAGAli Genco Gencay
- Gül ArgaGAGül Arga
- Selen KaragözlüSKSelen Karagözlü
- Mehmet Gökhan RamogluMRMehmet Gökhan Ramoglu
- Halil ÖzdemirHÖHalil Özdemir
- Tayfun UcarTUTayfun Ucar
- 11 August 2021
- journal article
- research article
- Published by Georg Thieme Verlag KG in Journal of Pediatric Intensive Care
- Vol. 12 (01) , 037-043
Abstract
Background Multisystem inflammatory syndrome in children (MIS-C) is characterized by persistent fever, abdominal pain, vomiting, diarrhea, rash, conjunctivitis, headaches, and mucocutaneous manifestations and it can cause circulatory dysfunction, resulting in hypotension, shock, and end-organ injury in the heart and other organs and possibly death. In this study, we aimed to analyze the clinical spectrum, treatment options and outcomes of children with MIS-C who were admitted to our pediatric intensive care (PICU). Materials and Methods Clinical and laboratory findings and treatment of the patients admitted to the PICU with MIS-C between April 2020 and January 2021 were recorded, and their outcomes were evaluated. Results Nineteen patients with a median age of 12.5 years (interquartile range (IQR): 5.8–14.0 years) were admitted. Eleven (57.8%) were males. The most frequent clinical and laboratory features were fever (100%), abdominal pain (94.7%), rash (63.1%), headache (68.4%), diarrhea (47.3%), seizure (10.5%), cardiac dysfunction (52.6%), acute kidney injury (26.3%), lymphopenia (84.2%), and thrombocytopenia (36.8%). However, 8 patients needed mechanical respiratory support, 11 patients needed inotropes, 2 patients needed plasma exchange, and 1 patient needed continuous renal replacement therapy. All patients received corticosteroids, 17 patients (89.2%) received intravenous immunoglobulin, 2 patients received anakinra, 10 patients received acetylsalicylic acid, and 6 patients received enoxaparin. Median PICU length of stay was 3 days (IQR: 2–5) and only one patient died. Conclusion In conclusion, MIS-C may present with a variety of clinical manifestations, and it can lead to life-threatening critical illness. Most children need intensive care and the response to immunomodulation is usually favorable.Keywords
This publication has 21 references indexed in Scilit:
- Imaging Findings in Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)American Journal of Roentgenology, 2021
- Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C)Pediatrics, 2020
- Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS–CoV-2Journal of Clinical Investigation, 2020
- The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19Cell, 2020
- Echocardiographic Findings in Pediatric Multisystem Inflammatory Syndrome Associated With COVID-19 in the United StatesJACC, 2020
- COVID-19 Associated Hemophagocytic Lymphohistiocytosis and Coagulopathy: Targeting the DuumvirateIndian Pediatrics, 2020
- COVID-19–Associated Multisystem Inflammatory Syndrome in Children — United States, March–July 2020MMWR. Morbidity and Mortality Weekly Report, 2020
- Multisystem Inflammatory Syndrome in Children in New York StateNew England Journal of Medicine, 2020
- Multisystem Inflammatory Syndrome in U.S. Children and AdolescentsNew England Journal of Medicine, 2020
- The Ideal Time Interval for Critical Care Severity-of-Illness AssessmentPediatric Critical Care Medicine, 2013